8-K filing — DSS, INC. (DSS)
Filed: 2026-09-21 AccNo: 0001493152-26-043561 Size: 650 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Filings · News reference
DSS, Inc. announced that the SEC declared effective the Form F-4 registration statement for the proposed business combination involving its subsidiary, Impact Biomedical Inc., and Zoar Limited.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-09-21 AccNo: 0001493152-26-043561 Size: 650 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
DSS, Inc. (NYSE:DSS), a diversified technology company with experience in enterprise IT services, digital transformation, cybersecurity and authentication technologies, today announced the launch of DSS Robotics, a new
DSS, Inc. announced on September 4, 2026, that it has decided not to proceed with its previously announced public offering of Common Stock due to limited capacity under its existing shelf registration statement. The company continues to explore alternative capital-raising options while remaining focused on shareholder value creation.
DSS, Inc. (NYSE:DSS) (the "Company"), a multinational company operating across diverse industries including product packaging, biotechnology, commercial lending, and securities and investment management, today
DSS, Inc. announced the commencement of a public offering of Common Stock on the NYSE American under ticker DSS. The company intends to use net proceeds for general corporate and working capital needs. Aegis Capital Corp. is serving as the sole book-running manager. The offering is subject to market conditions and completion is not assured.